異位性皮膚炎 突破性治療

October 13, 2020

法國製藥賽諾菲(Sanofi)與合作夥伴再生元(Regeneron)於上月獲得美國食品藥物管理局(FDA)批准Dupilumab,一種注射型生物製劑,以治療12歲以上中度至重度嗜酸細胞性食道炎(EoE)患者,此批准是對EoE患者進行的3期臨床試驗數據Part A的結果。

 

此外,Dupilumab也於早前在美國與歐盟獲准治療中度至嚴重濕疹(異位性皮膚炎)六歲或以上的患者,它可以單獨使用,或與類固醇藥物一併使用。成為首個治療中度至嚴重異位性皮膚炎的生物製劑。

 

Dupilumab主要通過抑制兩種關鍵的蛋白,白細胞介素-4 (interleukin-4)和白細胞介素-13 (interleukin-13), 阻止它們所誘發的炎症反應。另外,它亦被批准用於中度至嚴重持續性哮喘患者。

 

 

 資料來源:

  • https://www.pharmaceutical-business-review.com/news/sanofi-regeneron-dupixent/?fbclid=IwAR3poUoYs3JHeT_77yDXZHNypkaABdEuvxzWvUNBf_18UhFGjnkZqeu9uIc

  • https://www.globenewswire.com/news-release/2020/05/26/2038798/0/en/Sanofi-FDA-approves-Dupixent-dupilumab-as-first-biologic-medicine-for-children-aged-6-to-11-years-with-moderate-to-severe-atopic-dermatitis.html?fbclid=IwAR2pOZsMLPJEmjePWBFuwLJrFgPFZZTWryJNuT54zaU-GHSnhC3Uw50uxTA

  • https://newsroom.regeneron.com/news-releases/news-release-details/fda-approves-dupixentr-dupilumab-first-biologic-medicine/?fbclid=IwAR2V9PYVq9cq8MHw-Ty-ADboZ9iMywQkYSz10Hd7VkEXJUQG5O6lwz-n4K0

Share on Facebook
Share on Twitter
Please reload

​關於我們

香港醫療站的創主是希望建立一個全新的網上平台,為香港市民提供最新最全面的醫學資訊。

 HKMED
  • Facebook Basic Black
  • Black Instagram Icon
  • Black Twitter Icon

HKMed Publications, Hong Kong.

© 2020 All rights reserved.

Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.